

Research Article

One pot synthesis of conjugated chalcone-quinoxalines using an organocatalyst under ultrasonic mediation

Kiana Darvishi

Department of chemistry, Takestan Branch, Islamic Azad University, Takestan, Iran

ARTICLE INFO:

Received: 8 July 2021

Accepted: 21 August 2021

Available online: 25 August 2021

☑: K. Darvishi kianadarvishi@yahoo.com

ABSTRACT

Ultrasonic irradiation was effectively used for the synthesis of one pot chalcon-quinoxaline derivatives with high efficiency and short time. The products are obtained by mixing parahydroxy acetophenone and various aldehydes or parahydroxy benzaldehyde with different ketones and then adding 2,6-dichloroquinoxaline, in the presence of catalytic amounts of pyrrolidine as a organocatalyst and DMF as a solvent. These conjugated chalcon-quinoxaline derivatives have been shown to have good anticancer activity.

Keywords: Ultrasonic mediation, Organocatalysts, Chalcone, Quinoxaline, Chalcon-quinoxaline

1. Introduction

Chalcones are widely found in nature and have a variety of biological activities including antioxidants [1], hypnotics [2], anti-inflammatory [3], anti-obesity [4], antiviral [5] antimicrobial [6], antiprotozoal [7] and antitumor [8]. Quinoxaline is also a member of heterocyclic compounds with nitrogen at position 1, 4 on the ring. Quinoxaline derivatives also have a wide range of biological activities, such as anti-tuberculosis [9], antimicrobial [10], anti-inflammatory [11], antioxidants [12], anti-HIV [13], kinase inhibitors [14] and anti-

cancer [15]. Numerous reports have shown that conjugated quinoxaline and chalcones (chalcone-quinoxalins) show good anti-cancer activity [16-20].

2. Experimental

2.1 General Experimental Procedure for preparation of chalcon-quinoxalines

Pyrrolidine (0.5 mmol) in 3 ml DMF was added to a mixture of parahydroxy benzaldehyde 1 (1 mmol) and aromatic ketone 2 (1 mmol) or a mixture of parahydroxy acetophenone 5 (1 mmol) and aromatic aldehyde 6 (1 mmol) and was sonicated for a period of time. The progress of the reaction was monitored by TLC using petroleum ether/ethyl acetate (4: 1). Then 2,6-dichloroquinoxaline 3 (1 mmol) was added to the reaction vessel and sonicated. Completion of the reaction was followed by TLC. After completion of the reaction, cold water was added dropwise to the mixture and the formed solid was filtred and washed with cold water. The crude product was then recrystallized from methanol, washed and dried to give products 4a-f and 7a-h. All obtained products are known compounds [20] and were confirmed and identified by melting point.

Scheme 1. Three-component synthesis of 4a

Table 1. Reactions of parahydroxy benzaldehyde 1 with Aromatic ketones 2

Entry	Ketone	Time (min) Product	Yield (%)	m.p. (° C)
1	4-CH ₃ -C ₆ H ₄	25	CI N 4a	81	153-155
2	4-OCH ₃ -C ₆ H ₄	20	CI NO 4b	86	145-148
3	4-Cl-C ₆ H ₄	25	CI NO 4c CI	80	177-180
4	2,4-diCl-C ₆ H ₃	30	CI NO CI 4d CI	82	154-155
5	2-Cl-C ₆ H ₄	25	CI N 4e 4e	84	142-145
6	2-F-C ₆ H ₄	25	CI N 4f 4f	78	148-150

Scheme 2. Three-component synthesis of 7a

Entry	Aldehyde	Time (min)	Product	Yield (%)	m.p. (° C)
1	4-CH ₃ -C ₆ H ₄	25	CI N 7a	85	188-190
2	3-OCH ₃ -C ₆ H ₄	20	CI N 7b	90	138-140
3	4-Cl-C ₆ H ₄	25	CI N 7c CI	85	220-221
4	2,4-diCl-C ₆ H ₃	25	CI NO TO CI	86	138-140
5	2-Cl-C ₆ H ₄	25	CI N 7e CI	89	173-175
6	2-F-C ₆ H ₄	30	CI N O F	83	167-169
7	$\mathrm{C_6H_4}$	25	CI N 7g	91	195-197
8	2,4-diOCH ₃ - C ₆ H ₃	20	CI N 7h 0	94	188-190

 $\textbf{Table 2.} \ Reactions \ of parahydroxy \ acetophenone \ 5 \ with \ Aromatic \ aldehydes \ 6$

3. Results and discussion

First, the optimal conditions for one pot synthesis **4a** (Figure 1) from the three starting materials parahydroxy benzaldehyde **1**, 4-methyl acetophenon **2a** and 2,6-dichloro quinoxaline **3** were

investigated in the presence of various catalysts, solvents and conditions, and the results showed that the shortest reaction time and highest efficiency were related to the use of pyrrolidine and dimethyl formamide under ultrasound radiation. For this purpose, triethyl amine, diethyl amine, morpholine and pyrrolidine organocatalysts were used under ultrasound. The reaction under reflux conditions was also investigated, which showed the heat causes more increase in by-products and a longer time than the same reaction under ultrasound radiation. Therefore, the products were obtained with less efficiency in reflux conditions. Solutions of dimethyl formamide, dimethyl sulfoxide, ethanol and water were also compared with each other to complete the optimization result. The optimization results are given in Table 1.

Entry Condition Solvent Time (min) Yield (%) Organocatalyst Et_3N **DMF** 60 7)))) 13 Et₂NH **DMF** 60)))) Morpholine **DMF** 60)))) 0 None)))) **DMF** 60 5 Pyrrolidine **DMF** 25 81)))) 6 Pyrrolidine **DMF** 45 Reflux 60 Pyrrolidine 25 DMSO 55)))) 8 25 Pyrrolidine **EtOH** 30)))) 9 Pyrrolidine)))) H_2O 60 25 10 Pyrrolidine DMF 60 0 None

Table 3. Optimization of the reaction conditions for the synthesis of **4a**.

4. Conclusion

The purpose of this article is to find an efficient method for the synthesis of chalconequinoxaline derivatives with anti-cancer properties. The single-vessel reaction makes the purification and separation processes with fewer steps and more ease. On the other hand, using of pyrrolidine due to the benefits of organocatalyst was introduced. Ultrasound mediatin also shortens the reaction time and results in fewer by-products.

References:

[1] E ,Polo; N., Ibarra-Arellano, L; Prent-Penaloza, A ,Morales-Bayuelo, J.; Henao, A ; Gald_amez, M; Guti_errez, *Bioorg. Chem.* 90 (2019) 103034.

- [2] S.Cho, S.Kim, Z.Jin, H.Yang, D.Han, N.-I. Baek, J J.o, C.-W.Cho, P J.-H.ark, M.Shimizu, Y.-H.Jin, *Biochem. Biophys. Res. Commun.* 413 (2011) 637–642.
- [3] Y.-L Tang, X.Zheng, Y.Qi, X.-J.Pu, B. Liu, X.Zhang, X.-S.Li, W.-L.Xiao, C.-P.Wan, Z.-W. Mao, *Bioorg. Chem.* 98 (2020) 103748.
- [4] M. R.El Sayed Aly, A H. H.bd El Razek Fodah, S. Y. Saleh, Eur. J. Med. Chem. 76 (2014) 517–530.
- [5] X. H.Gan, D. Y.Hu, Y. J.Wang, L. Yu, B. A. Song, J. Agric. Food Chem. 65 (2017) 4367–4377.
- [6] R.Xia, T.Guo, J.He, M.Chen, S.Su, S.Jiang, X.Tang, Y.Chen, W.Xue, *Monatsh. Chem.* 150 (2019) 1325–1334.
- [7] F.Hayat, E.Moseley, A.Salahuddin, R. L.Van Zyl, A.Azam, *Eur. J. Med. Chem.* 46 (2011) 1897–1905.
- [8] H.Cong, X.Zhao, B. T.Castle, E. J.Pomeroy, B.Zhou, J.Lee, Y.Wang, T.Bian,; Z.Miao,W.Zhang, *Mol. Pharm.* 15 (2018) 3892–3900.
- [9] P.Ramalingam, S.Ganapaty, C. B..Rao, *Bioorg. Med. Chem. Lett.* 20 (2010) 406–408.
- [10] H. M.Patel, V.Bhardwaj, P.Sharma, N. M. N.oolvi, S.Lohan, B. S.ansal, A. Sharma, J. Mol. Struct. 1184 (2019) 562–568.
- [11] A. J.Ruiz-Alcaraz, M.Trist_an-Manzano, A.Guirado, J.G_alvez, M.Mart_inez-Esparza, P.Garc 1a-Pe~narrubia, *Eur. J. Pharm. Sci.* 99 (2017) 292–298.
- [12] K.Saravana Mani, B.Murugesapandian, W.Kaminsky, S. P. Rajendran, *Tetrahedron Lett*. 59 (2018) 2921–2929.
- [13] S. B. Patel, B. D. Patel, C.Pannecouque, H. G. Bhatt, Eur. J. Med. Chem. 117 (2016) 230–240.
- [14] S. C.Kim, P. R.Boggu, H. N.Yu, S. Y.Ki, J. M.Jung, K Y. S.im, G. M.Park, S. H.Ma, I. S.Kim, Y. H. Jung, *Bioorg. Med. Chem. Lett.* 30 (2020) 127189.

- [15] Z.Ghanbarimasir, A.Bekhradnia, M. K.orteza-Semnani, A. Rafiei, R. N.azzaghi-Asl, M. Kardan, *Spectrochim Acta A Mol. Biomol. Spectrosc.* 194 (2018) 194, 21–35.
- [16] T S.ariq, K.Somakala, M. Amir, Eur. J. Med. Chem. 143 (2018) 542–557.
- [17] T. R.Mielcke, M A.ascarello, Filip E.pi-Chiela, R. F. Zanin, G.Lenz, P. C.Leal, L. D.Chiaradia, C L. D.hirardia, R. A.Yunes, R. J.Nunes, *Eur. J. Med. Chem.* 48 (2012) 255–264.
- [18] V.Desai, S.Desai, S. N.Gaonkar, Pa U.lyekar, S. D.Joshi, S. K.Dixit, Bioorg. *Med. Chem. Lett.* 27 (2017) 2174–2180.
- [19] M.Alswah, A. H.Bayoumi, K.Elgamal, A. Elmorsy, S. Ihmaid, H. E. A. Ahmed, *Molecules*. 23 (2017) 23, 48.
- [20] X.Ma, D.Wang, G.Wei, Q.Zhou, X. Gan, Synthetic Communications. 51 (2021) 1363-1372.